Financial Performance - The company's operating revenue for 2020 was CNY 928,511,813.36, representing a 40.01% increase compared to CNY 663,194,736.53 in 2019[26]. - The net profit attributable to shareholders for 2020 was CNY 227,744,103.42, which is an increase of 108.47% from CNY 109,246,252.70 in 2019[26]. - The net cash flow from operating activities for 2020 was CNY 261,831,612.30, up 86.89% from CNY 140,103,014.96 in 2019[26]. - The basic earnings per share for 2020 was CNY 0.72, a 111.76% increase from CNY 0.34 in 2019[26]. - The total assets at the end of 2020 were CNY 2,028,803,645.60, reflecting a 6.47% increase from CNY 1,905,460,495.00 at the end of 2019[26]. - The company reported a net asset attributable to shareholders of CNY 1,709,645,282.25 at the end of 2020, which is a 3.11% increase from CNY 1,658,042,540.88 at the end of 2019[26]. - The company achieved a weighted average return on equity of 13.86% in 2020, an increase of 7.18 percentage points from 6.68% in 2019[26]. - The company reported a total revenue of 373.77 million RMB for the year 2020[168]. - The company achieved a total R&D expenditure of ¥114.84 million, accounting for 12.37% of total revenue[81]. - The company reported a significant increase in sales for the poultry vaccine segment, with a revenue growth of 323.37% for the five-in-one inactivated vaccine[113]. Dividends and Shareholder Returns - The company plans to distribute cash dividends of RMB 5 per 10 shares, totaling an estimated cash dividend of RMB 157.32 million (including tax) based on the adjusted total share capital as of December 31, 2020[6]. - The company distributed a cash dividend of 2 RMB per share, totaling 63.18264 million RMB, based on a shareholder base of 315,913,200 shares[142]. - The company reported a net profit of 227,744,103.42 RMB for 2020, with a cash dividend amounting to 133,522,943.54 RMB, which is 58.63% of the total[143]. - The company’s cash dividend distribution has shown a consistent increase over the past three years, reflecting a commitment to returning value to shareholders[143]. - The company has not proposed a cash profit distribution plan for the reporting period despite having positive distributable profits[143]. - The company repurchased shares for a total cash payment of 134 million yuan, achieving good shareholder returns[198]. Governance and Compliance - The company has received a standard unqualified audit report from the accounting firm, ensuring the accuracy and completeness of the financial report[5]. - The company has confirmed that all board members attended the board meeting, ensuring governance and oversight[5]. - The company has not violated decision-making procedures in providing guarantees, maintaining compliance with regulations[8]. - The company has not faced any situations where more than half of the directors could not guarantee the authenticity and completeness of the annual report[8]. - The company is committed to ensuring the financial report's authenticity, accuracy, and completeness, as stated by its responsible personnel[5]. - The actual controller and major shareholders have committed to not engaging in any business that competes with the company during their tenure[144]. - The company’s major shareholders are subject to a lock-up period of two years post-IPO, with specific conditions for share reduction[144]. - The company has made commitments to ensure the accuracy and completeness of its IPO prospectus, with legal responsibilities for any misrepresentation[144]. Research and Development - The company’s R&D investment has consistently exceeded 10% of its revenue over the past three years, leading to the acquisition of 55 new veterinary drug certificates and 496 invention patent applications[45]. - The company has developed a range of innovative vaccines, including gene-engineered and multi-valent vaccines, which are crucial for disease control in livestock[35]. - The company is actively developing a vaccine for African swine fever, with clinical trials already completed in multiple locations[56]. - The company is focusing on expanding its product line with new veterinary drugs and vaccines[106]. - The company has made significant advancements in R&D for new veterinary products, including a new inactivated vaccine for avian influenza[106]. - The company has received clinical trial approval for a canine distemper and parvovirus combined live vaccine[109]. - The company is developing a vaccine for Seneca Valley virus, currently in the new veterinary drug registration phase[97]. - The company is conducting clinical trials for a live vaccine against pseudorabies in pigs[97]. Market and Sales Strategy - The company operates in the veterinary biopharmaceuticals sector, focusing on the R&D, production, and sales of veterinary biological products and chemical drugs, with over 50 biological products and more than 200 chemical drugs available[35]. - The company utilizes a sales model that includes distribution, direct sales, and government procurement to effectively reach various customer segments[41]. - The company has established a strong sales network with 4,152 terminal distributors and 3,179 cooperative large-scale farms by the end of the reporting period[61]. - The company’s marketing strategy focuses on large group customer development and optimizing regional agency management, leading to significant sales growth[60]. - The company is focusing on international market expansion and high-end brand cultivation, aiming for comprehensive output in products, technology, and capital[126]. - The company plans to implement a comprehensive marketing management system, emphasizing standardized, process-oriented, and digitalized marketing strategies to improve efficiency[130]. Risks and Challenges - The company has outlined various risks faced in its production and operations, which are detailed in the report[8]. - The company faces risks related to animal disease outbreaks, regulatory changes, intensified market competition, product development challenges, and product quality assurance[133][136][137][138][139]. - The implementation of the new veterinary drug GMP has raised industry entry barriers and accelerated the exit of outdated production capacity, leading to increased industry concentration[125]. - The company emphasizes the importance of compliance and innovation in response to stringent regulatory policies affecting the veterinary drug industry[136]. Financial Management and Investments - The company has entrusted cash asset management with a total of 622.2 million RMB in principal for guaranteed products[180]. - Non-guaranteed financial products amounted to 465 million RMB, with an outstanding balance of 220 million RMB[180]. - The company has a total of 1,200,000 RMB in floating return wealth management at Agricultural Bank, with an actual return of 3,110 RMB[189]. - The company has a future plan for wealth management, although specific details were not disclosed[183]. - The company has recovered 99,020 RMB from a 5,000,000 RMB investment in floating return wealth management at CITIC Bank[186].

Financial Performance - Net profit attributable to shareholders was CNY 160,471,917.44, representing an increase of 68.79% year-on-year[17]. - Operating income for the period was CNY 639,601,996.04, reflecting a growth of 38.28% compared to the same period last year[19]. - Cash flow from operating activities reached CNY 149,050,745.91, up 109.41% year-on-year[17]. - The revenue from pig vaccines was CNY 170,972,778.43, an increase of 128.71% compared to the previous year[19]. - The revenue from poultry vaccines and antibodies was CNY 260,249,801.64, showing a growth of 23.18% year-on-year[19]. - The company reported a net profit excluding non-recurring gains and losses of CNY 125,439,659.38, up 82.73% year-on-year[17]. - Basic earnings per share rose to CNY 0.51, a 70.00% increase from the previous year[17]. - The company's net profit for the first three quarters of 2020 was ¥647,434,110.71, compared to ¥470,939,716.89 in the same period of 2019, reflecting a growth of approximately 37%[45]. - The net profit attributable to shareholders for Q3 2020 was ¥40.45 million, up 35% from ¥29.99 million in Q3 2019[52]. - The total profit for Q3 2020 was ¥48.32 million, compared to ¥34.18 million in Q3 2019, reflecting a growth of 41%[52]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,881,525,302.79, a decrease of 1.26% compared to the end of the previous year[17]. - Total liabilities increased to ¥254,809,545.03 from ¥247,417,954.12[37]. - Owner's equity remained stable at ¥321,496,000.00[37]. - Accounts receivable increased by 54.68% to ¥198,858,360.24 due to higher operating income[27]. - Other receivables decreased by 86.12% to ¥4,538,165.91 primarily from the recovery of loans by a subsidiary[27]. - Construction in progress rose by 56.66% to ¥49,243,116.46 due to increased investment in construction projects[27]. - Other non-current assets increased by 107.17% to ¥70,325,773.36 mainly from prepayments for engineering equipment[27]. - Total assets as of September 30, 2020, amounted to ¥1,658,435,872.24, a decrease from ¥1,768,603,489.29 at the end of 2019[43]. - The total liabilities as of September 30, 2020, were ¥162,767,740.09, down from ¥168,847,352.59 at the end of 2019[45]. - The company reported a total equity attributable to shareholders of ¥1,495,668,132.15, down from ¥1,599,756,136.70 at the end of 2019[45]. Cash Flow - Cash received from operating activities increased by 108.60% to ¥74,322,390.02 due to loan recoveries and increased government subsidies[30]. - Cash inflow from operating activities totaled CNY 664,903,082.43, an increase from CNY 488,878,915.40 in the same period last year, marking a growth of about 36%[59]. - Cash outflow from operating activities was CNY 515,852,336.52, compared to CNY 417,700,979.10 in the previous year, representing an increase of approximately 23.5%[63]. - The net cash flow from operating activities was CNY 149,050,745.91, significantly higher than CNY 71,177,936.30 in the same quarter of 2019, indicating an increase of about 109%[63]. - Cash flow from investment activities showed a net outflow of CNY 39,395,366.07, an improvement from a net outflow of CNY 169,443,698.40 in the previous year[63]. Operational Metrics - The weighted average return on net assets increased by 4.01 percentage points to 9.84%[17]. - Total operating revenue for Q3 2020 reached ¥225,675,942.92, a significant increase from ¥151,357,226.59 in Q3 2019, representing a growth of approximately 49%[45]. - Total operating costs for Q3 2020 were ¥198,613,854.26, up from ¥121,728,772.78 in Q3 2019, indicating an increase of about 63%[45]. - The company's operating revenue for Q3 2020 was approximately ¥117.96 million, a 39% increase from ¥84.85 million in Q3 2019[55]. - The company's basic earnings per share for Q3 2020 was ¥0.51, an increase from ¥0.30 in Q3 2019[54]. Research and Development - Research and development expenses in Q3 2020 reached ¥37.20 million, significantly higher than ¥10.62 million in Q3 2019, indicating a focus on innovation[55]. Financial Management - The financial expenses for Q3 2020 were reduced to -¥105.83 thousand from -¥1.59 million in Q3 2019, showing improved financial management[55]. - The company noted a significant adjustment in the financial statements due to the implementation of new accounting standards[77].

Financial Performance - The company reported a significant increase in revenue for the first half of 2020, with a year-on-year growth of 15%[2] - The company's operating revenue for the first half of 2020 reached ¥421,758,167.79, representing a year-on-year increase of 31.97%[21] - Net profit attributable to shareholders was ¥120,026,748.15, an increase of 84.44% compared to the same period last year[21] - The net profit after deducting non-recurring gains and losses increased by 129.14%, amounting to ¥102,230,868.70[21] - The total operating income for the reporting period was 319,582,490.30, an increase of 31.97% compared to the same period last year[54] - The total profit for the first half of 2020 was 138,256,504.54, compared to 72,072,701.66 in the first half of 2019, representing an increase of approximately 92.0%[151] - The company reported a financial income of -1,913,499.29 for the first half of 2020, an improvement compared to -3,124,403.86 in the first half of 2019[148] - The company achieved a gross profit margin of approximately 68.7% in the first half of 2020, compared to 67.4% in the same period of 2019[152] Research and Development - The company has allocated 15% of its annual budget towards new technology research and development initiatives[2] - The company invested 41.28 million RMB in R&D, accounting for 9.92% of its main business revenue[47] - The company has established three national-level R&D platforms to enhance its innovation capabilities in the veterinary medicine sector[31] - The company is actively developing multi-valent poultry vaccine projects to enhance product technology barriers and upgrade poultry vaccine products[48] - The company has completed the upgrade of the high pathogenic avian influenza vaccine production workshop and is preparing for GMP acceptance[53] Market Expansion and Product Development - User data indicates a growing customer base, with an increase of 20% in active users compared to the previous year[2] - The company has set a future outlook with a revenue target of 1 billion yuan for the next fiscal year, representing a 25% increase from the current year[2] - New product development includes the launch of a novel vaccine, which is expected to capture 30% of the market share within the first year of release[2] - The company is expanding its market presence, targeting an additional 10 provinces in the next 12 months[2] - The company achieved sales revenue of 0.97 billion, 1.81 billion, and 1.27 billion for pig vaccines, poultry vaccines and antibodies, and chemical drugs respectively, representing year-on-year growth of 79.45%, 26.02%, and 21.14%[49] Financial Position and Cash Flow - The company's cash and cash equivalents at the end of the reporting period were 260,896,521.34, a 52.48% increase from 171,105,020.19 in the previous year[59] - The company’s cash flow from operating activities was 2,386,018.47, showing a significant increase due to higher cash received from sales of goods and services[56] - The company’s cash flow from operating activities generated a net amount of RMB 67.40 million, significantly up from RMB 2.39 million in the first half of 2019[160] - The total cash inflow from operating activities of RMB 257,836,505.27, up from RMB 187,827,282.02 in the first half of 2019, marking a growth of approximately 37.2%[164] Risks and Challenges - The management highlighted potential risks, including regulatory changes that could impact product approvals and market access[2] - The company is facing external risks including policy changes, animal epidemic risks, and market competition, which could impact operational goals[72] - Internal risks include product development and quality risks, which may delay or hinder the progress of new product launches[78][79] Shareholder and Governance Matters - The company reported a commitment to not engage in any business activities that compete with its existing operations during the tenure of its controlling shareholder, Zhang Xuke[86] - The controlling shareholder has committed to not invest in or operate any similar businesses that would compete with the company, ensuring no conflicts of interest[86] - The company has established a framework for compensating investors in case of losses due to non-fulfillment of commitments by its executives[88] - The company has not reported any breaches of commitments during the reporting period, indicating strict compliance with its obligations[86] Environmental and Compliance Issues - The company was listed as a key pollutant discharge unit by the Jiangsu Provincial Ecological Environment Department[109] - Wastewater treatment facilities are fully equipped and operating stably, with treated wastewater meeting discharge standards[112] - The company has implemented an emergency response plan for environmental incidents and conducts annual training[114] Shareholder Structure and Equity - A total of 5,957,000 shares were repurchased, accounting for 1.85% of the company's total share capital, with a total expenditure of approximately RMB 110.27 million[121] - The total number of common shareholders at the end of the reporting period was 11,085[124] - The top shareholder, Zhang Xuke, holds 107,619,672 shares, representing 33.47% of the total shares[124] - The second-largest shareholder, Sun Jinzhu, holds 45,947,048 shares, accounting for 14.29%[124]

B ulike 股票代码：603566 公司简称：普 莱 柯 普莱柯生物工程股份有限公司 2020年第一季度报告 创 / / / / 未 / 来 2020 年第一季度报告 一、 二、 11Í 四、 目录 | --- | |----------------| | | | 重要提示 . | | 公司基本情况 . | | 重要事项 . | | 附录 . | 2 / 18 2020 年第一季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人张许科、主管会计工作负责人胡伟及会计机构负责人（会计主管人员）裴莲凤保 证季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 | --- | --- | --- | --- | |------------------------------------------------|---------- ...

Financial Performance - The company's operating revenue for 2019 was CNY 663,194,736.53, representing a 9.07% increase from CNY 608,059,265.46 in 2018[27]. - The net profit attributable to shareholders for 2019 was CNY 109,246,252.70, a decrease of 19.44% compared to CNY 135,614,826.19 in 2018[27]. - The net cash flow from operating activities for 2019 was CNY 140,103,014.96, showing a 10.95% increase from CNY 126,271,903.35 in 2018[30]. - The total assets at the end of 2019 were CNY 1,905,460,495.00, a slight increase of 0.13% from CNY 1,903,079,629.30 at the end of 2018[30]. - The net assets attributable to shareholders at the end of 2019 were CNY 1,658,042,540.88, reflecting a 1.37% increase from CNY 1,635,570,001.83 at the end of 2018[30]. - The basic earnings per share for 2019 were CNY 0.34, down 19.05% from CNY 0.42 in 2018[30]. - The weighted average return on net assets for 2019 was 6.68%, a decrease of 1.81 percentage points from 8.49% in 2018[30]. - The company reported a decrease of 27.06% in net profit after deducting non-recurring gains and losses, amounting to CNY 63,667,919.46 in 2019 compared to CNY 87,284,030.87 in 2018[27]. - The diluted earnings per share for 2019 were also CNY 0.34, consistent with the basic earnings per share[30]. - The company's total revenue for the reporting period was approximately ¥663.19 million, representing a year-on-year increase of 9.07%[71]. Dividend Distribution - The company plans to distribute a cash dividend of RMB 2.0 per 10 shares, totaling an estimated cash dividend of RMB 63.1826 million (including tax) based on the adjusted share capital as of December 31, 2019[8]. - In 2019, the cash dividend amounted to 63.18 million RMB, representing 57.84% of the net profit attributable to ordinary shareholders in the consolidated financial statements[163]. - The company distributed a cash dividend of 0.3 RMB per share, totaling 97.12 million RMB for the 2018 fiscal year, based on a share capital of 32.374 million shares[161]. - The company distributed a total of 97.122 million yuan in dividends (including tax) during the reporting period, achieving good shareholder returns[197]. Audit and Compliance - The company has received a standard unqualified audit report from Lixin Certified Public Accountants, ensuring the financial report's authenticity and completeness[7]. - The board of directors and senior management have confirmed the accuracy and completeness of the annual report, taking legal responsibility for any misrepresentation[5]. - There are no non-operational fund occupations by controlling shareholders or related parties, nor any violations in decision-making procedures for external guarantees[10]. - The company committed to fulfilling all public promises made during the initial public offering (IPO) and will actively accept social supervision[168]. - The company’s prospectus is guaranteed to be free from false records or misleading statements, with legal responsibility for its accuracy and completeness[171]. - The company will halt cash dividend plans and executive compensation until all public commitments are fulfilled if any promises are not met[170]. - The company will stop major asset purchases or capital operations until compliance with commitments is achieved[170]. - The company’s commitment to transparency and accountability is emphasized to protect investor rights[171]. Operational Risks and Market Outlook - The company has outlined various operational risks in the report, advising investors to be aware of potential investment risks[10]. - The report includes a forward-looking statement risk declaration, indicating that future plans and strategies do not constitute a commitment to investors[9]. - The company emphasizes the importance of adhering to Good Manufacturing Practices (GMP) and other quality management standards in its operations[17]. - The report discusses the company's business overview and key financial indicators, highlighting its operational performance during the reporting period[13]. - The company has confirmed that all board members attended the board meeting, ensuring collective decision-making[6]. - The report includes a detailed analysis of the company's operational situation and future outlook, providing insights into market expansion and new product development strategies[13]. Research and Development - Research and development (R&D) investment totaled 90.82 million RMB, an increase of 23.62% year-on-year, with R&D expenses accounting for 13.92% of sales revenue[57]. - The company has established three national-level R&D platforms to enhance its innovation capabilities in veterinary pharmaceuticals[39]. - The company has accumulated 48 new veterinary drug certificates and 198 patent grants, including 12 international patents, demonstrating its commitment to innovation[50]. - The company is actively collaborating with various research institutions to develop vaccines for major animal diseases, including African swine fever and foot-and-mouth disease[58]. - The company has made significant advancements in the development of pet vaccines and therapeutic biological products, with several products entering the new veterinary drug registration phase[60]. - The company is focusing on R&D for next-generation genetically engineered vaccines and multi-valent vaccines, with a series of projects aimed at disease prevention in pigs and poultry[100]. - The company has emphasized intellectual property protection, filing a series of invention patents domestically and internationally for key products under development[100]. Market Expansion and Sales Strategy - The company employs a sales model that includes distribution, direct sales, and government procurement to reach various customer segments effectively[44]. - The company aims to improve its procurement efficiency through scientific management and professional processes[40]. - The veterinary vaccine and pharmaceutical market is expected to see increased penetration as the scale and intensification of livestock farming continue to rise[45]. - The company established strategic partnerships with large-scale breeding groups, resulting in a 30% year-on-year increase in sales to group clients[65]. - The company is actively pursuing market expansion through the introduction of new veterinary drugs and vaccines, enhancing its competitive position in the industry[119]. - The company is committed to ongoing research and development, with several products in the pipeline aimed at addressing various animal health needs[115]. Financial Investments and Assets - The company has a total of RMB 975 million in principal-protected financial investments, with an outstanding balance of RMB 315 million[189]. - The company has raised RMB 430 million in fundraising for principal-protected financial investments[189]. - The company has invested RMB 143 million in guaranteed return financial products, with an expected return of RMB 4 million[189]. - The company reported a long-term equity investment balance of ¥153.44 million, a decrease of 7.09% from the previous year[134]. Social Responsibility and Compliance - The company actively participates in social responsibility initiatives, particularly in response to the COVID-19 pandemic[196]. - The company has a focus on protecting employee rights and ensuring the legitimate rights of suppliers[196]. - The company adheres to environmental protection regulations, ensuring wastewater is treated effectively before discharge[200]. - During the COVID-19 pandemic, the company quickly organized production of a new generation of disinfectants and donated them for epidemic prevention[200]. - The company aims to build a globally influential Chinese veterinary medicine brand while actively participating in social welfare initiatives[200].

Financial Performance - Operating income for the first nine months was CNY 470,939,716.89, representing a year-on-year increase of 9.28%[18] - Net profit attributable to shareholders was CNY 95,069,749.45, down 20.17% from the previous year[18] - Basic earnings per share decreased by 18.92% to CNY 0.30[21] - Total operating revenue for Q3 2019 was CNY 151,357,226.59, an increase of 3.8% compared to CNY 145,670,260.90 in Q3 2018[51] - Net profit for Q3 2019 reached CNY 29,992,899.72, a decrease of 29.6% from CNY 42,654,958.33 in Q3 2018[54] - The company reported a total profit of CNY 34,176,748.74 for Q3 2019, compared to CNY 49,034,146.58 in Q3 2018[54] - Total profit for the first three quarters of 2019 was ¥68,885,203.71, a decrease of 48.2% compared to ¥132,831,833.51 in the same period of 2018[59] Revenue Breakdown - Revenue from pig vaccines decreased by 46.93% to CNY 74,754,639.81 compared to the same period last year[22] - Revenue from poultry vaccines and antibodies increased by 38.17% to CNY 211,273,553.69 year-on-year[22] - Revenue from chemical drugs rose by 32.44% to CNY 158,909,510.55 compared to the previous year[22] Cash Flow and Investments - The cash flow from operating activities for the first nine months was CNY 71,177,936.30, an increase of 15.37% year-on-year[18] - Cash received from operating activities increased by 71.97% to ¥35,628,931.70 from ¥20,718,049.94, primarily due to higher government subsidy receipts[32] - Cash paid for investments decreased by 42.96% to ¥868,456,447.00 from ¥1,522,550,000.00, reflecting a reduction in purchased financial products[32] - Cash inflow from investment activities totaled ¥760,305,481.78 in the first three quarters of 2019, a decrease of 50.0% from ¥1,516,496,123.09 in 2018[68] - Net cash flow from investment activities was -¥169,443,698.40 for the first three quarters of 2019, compared to -¥40,108,118.59 in 2018, indicating a significant decline[71] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,833,474,608.48, a decrease of 3.66% compared to the end of the previous year[18] - Total liabilities decreased from 267,509,627.47 to 199,283,657.19, a reduction of approximately 25.5%[42] - Current assets decreased from 850,115,215.76 to 707,381,613.51, a decline of about 16.7%[46] - Total assets decreased from 1,814,783,829.14 to 1,720,812,536.54, a decline of approximately 5.2%[48] - Total equity remained relatively stable, decreasing slightly from 1,635,570,001.83 to 1,634,190,951.29[42] Research and Development - Research and development expenses increased by 44.71% to ¥59,604,369.35 from ¥41,188,548.05, primarily due to higher external technical cooperation costs[32] - Research and development expenses for Q3 2019 amounted to CNY 14,204,049.87, an increase of 1.9% compared to CNY 13,931,818.74 in Q3 2018[51] Shareholder Information - The total number of shareholders at the end of the reporting period was 11,477[22] - Shareholders' equity reached ¥1,635,570,001.83, with retained earnings of ¥750,669,278.57[85] Market Strategy - The company plans to enhance its market expansion efforts and invest in new product development in the upcoming quarters[59]

Financial Performance - The company reported a total revenue of 100 million RMB for the first half of 2019, reflecting a year-on-year increase of 15%[18]. - The net profit attributable to shareholders reached 20 million RMB, representing a growth of 10% compared to the same period last year[18]. - The company's operating revenue for the first half of the year reached ¥319,582,490.30, representing a 12.02% increase compared to ¥285,290,183.23 in the same period last year[25]. - Net profit attributable to shareholders decreased by 14.86% to ¥65,076,849.73 from ¥76,434,737.79 year-on-year[25]. - Basic earnings per share fell by 16.67% to ¥0.20 from ¥0.24 in the same period last year[25]. - The company's total revenue for the reporting period was approximately ¥319.58 million, representing a year-on-year increase of 12.02%[58]. - The net profit attributable to the parent company for the first half of 2019 was CNY 41,027,274.77, down 46.5% from CNY 76,813,419.09 in the first half of 2018[171]. - Total comprehensive income for the first half of 2019 was CNY 41,027,274.77, down from CNY 76,813,419.09 in the first half of 2018[175]. Research and Development - Investment in R&D increased by 30% year-on-year, totaling 15 million RMB, to enhance product development capabilities[18]. - The company is currently in the clinical trial phase for three new vaccine products, expected to be launched by Q4 2019[18]. - The company is focused on R&D in animal biological products and chemical drugs, with a strategy of continuous innovation driven by market demand[30]. - The company aims to enhance R&D efficiency by establishing a series of technical platforms and optimizing operational processes[33]. - The company invested 45.40 million yuan in R&D, accounting for 14.21% of operating revenue, ensuring the smooth progress of R&D projects[52]. - Research and development expenses increased by 66.57% to ¥45.40 million, driven by higher external technical cooperation costs[58]. - The company is actively developing pet health products, with a rabies inactivated vaccine entering the new veterinary drug registration phase[51]. - The company has established several national-level technology innovation platforms to enhance its independent innovation capabilities[40]. - The company is collaborating with various research institutions to develop African swine fever vaccines and has achieved significant research results[49]. - The company is focusing on the development of key economic animal vaccines, including those for foot-and-mouth disease and avian influenza, to meet market demands[50]. Market Expansion and Strategy - Future outlook indicates a projected revenue growth of 20% for the second half of 2019, driven by new product launches and market expansion strategies[18]. - The company plans to enter two new regional markets in 2020, aiming to increase market share by 10% in those areas[18]. - The sales strategy includes a combination of distributor sales, direct sales to breeding groups, and government bidding[38]. - The company has initiated the construction of a digital marketing platform to enhance its marketing strategies in response to the African swine fever epidemic[53]. Financial Integrity and Governance - No non-operating fund occupation by controlling shareholders was reported, ensuring financial integrity[18]. - The company has no plans for significant mergers or acquisitions in the near term, focusing instead on organic growth strategies[18]. - The board of directors has approved a profit distribution plan, although specific details were not disclosed in the report[18]. - The company has acknowledged the high investment and long cycle associated with R&D in the veterinary drug industry, which typically takes around 6 years[77]. - The company has committed to publicly explaining any failure to fulfill public commitments and to compensate investors for any losses incurred[101]. - The company has a long-term commitment to transparency and accountability in its financial disclosures[94]. Environmental Compliance - The company has implemented a comprehensive environmental monitoring plan, ensuring compliance with national environmental regulations[126]. - The company actively promotes clean production and enhances internal environmental management to reduce pollutant emissions[129]. - The company has established a response plan for environmental emergencies and conducts annual training[125]. - The company's wastewater treatment facilities are fully equipped and operate stably, ensuring effective treatment before discharge[122]. Shareholder Information - The total number of shares after the recent changes is 322,570,000, with a decrease of 1,170,000 shares[130]. - The largest shareholder, Zhang Xuke, holds 107,619,672 shares, representing 33.36% of total shares[136]. - The second-largest shareholder, Sun Jinzong, holds 50,982,948 shares, representing 15.81% of total shares, with 5,898,900 shares pledged[136]. - The company reported no changes in the shareholding of directors during the reporting period[140]. - The company has not disclosed any new strategies or market expansions in the current report[140]. Cash Flow and Assets - The company's cash and cash equivalents decreased from ¥451,364,287.25 in December 2018 to ¥171,105,020.19 by June 30, 2019, representing a decline of approximately 62%[147]. - Accounts receivable increased from ¥140,799,136.04 in December 2018 to ¥178,612,988.10 in June 2019, indicating a growth of about 27%[147]. - Inventory rose from ¥96,567,181.14 in December 2018 to ¥116,256,667.18 in June 2019, reflecting an increase of approximately 20%[147]. - Total current assets decreased from ¥1,002,712,425.38 in December 2018 to ¥889,117,636.60 in June 2019, a reduction of around 11%[147]. - Total assets decreased from ¥1,903,079,629.30 in December 2018 to ¥1,820,468,215.57 in June 2019, a decline of approximately 4.4%[153].

证券代码：603566 证券简称：普莱柯 公告编号：2019-026 普莱柯生物工程股份有限公司 关于参加 2019 年河南上市公司投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2019 年 6 月 27 日（星期四），下午 14:30-17:30 会议召开地点：投资者互动平台（http://rs.p5w.net） 会议召开方式：网络在线交流 一、会议类型 为便于广大投资者更加深入全面地了解普莱柯生物工程股份有限公司（以下 简称"公司"）2018 年年报、公司治理、发展战略、经营状况、股权激励、投资 者保护、可持续发展等投资者所关心的问题，公司决定参加由河南上市公司协会 主办的"互动感受诚信 沟通创造价值"—2019 年河南上市公司投资者网上集体接 待日活动。 二、会议召开时间及方式 1、会议时间：2019 年 6 月 27 日（星期四），下午 14:30-17:30 2、召开方式：网络在线交流 3、出席人员：董事会秘书赵锐先生 三、投资者参加方式 本次活 ...

Financial Performance - Net profit attributable to shareholders decreased by 62.6% year-on-year to CNY 14,418,319.35, primarily due to increased R&D expenses for major animal disease vaccines[11] - The company reported a basic earnings per share of CNY 0.04, a decrease of 66.67% compared to the same period last year[11] - Operating profit decreased to CNY 10,850,502.17 from CNY 42,623,908.55, a decline of approximately 74.6%[39] - Net profit for the quarter was CNY 14,418,319.35, down from CNY 38,551,260.14, indicating a decline of about 62.6%[41] - The company reported a total profit of CNY 16,260,625.51, down from CNY 44,358,843.71, indicating a decline of approximately 63.4%[39] Revenue and Sales - Revenue from pig vaccines decreased by 37.67% to CNY 32,186,350.04, impacted by a significant decline in pig inventory due to African swine fever[14] - Revenue from poultry vaccines and antibodies increased by 20.31% to CNY 55,153,219.96, indicating a positive trend in this segment[14] - Revenue from chemical drugs rose by 22.20% to CNY 55,567,473.39, reflecting strong performance in this category[14] - Total operating revenue for the first quarter was CNY 147,308,624.78, an increase from CNY 143,820,632.50 in the previous year, representing a growth of approximately 3.4%[39] Expenses and Costs - Operating cash flow net outflow increased by 282.98% year-on-year to CNY -48,393,711.45, mainly due to increased year-end bonuses and technical cooperation costs[14] - Total operating costs rose to CNY 139,725,241.76 from CNY 108,878,788.49, marking an increase of about 28.3%[39] - Research and development expenses surged by 170.69% to ¥32,121,004.20, primarily due to increased technical collaboration costs[20] - The company reported a significant increase in cash paid to employees, totaling CNY 54,232,936.27, up from CNY 40,387,468.11 year-over-year[50] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,883,129,230.75, a decrease of 1.05% compared to the end of the previous year[11] - The total number of shareholders at the end of the reporting period was 11,173[15] - Total liabilities decreased from ¥267,509,627.47 to ¥233,140,909.57, a reduction of approximately 12.8%[30] - Total equity increased from ¥1,635,570,001.83 to ¥1,649,988,321.18, reflecting a growth of about 0.9%[30] - Cash and cash equivalents decreased from ¥385,246,166.19 to ¥264,578,589.29, a decline of approximately 31.2%[33] Cash Flow - The net cash flow from operating activities decreased by 282.98% to -¥48,393,711.45, mainly due to the payment of last year's year-end bonuses and increased technical collaboration costs[20] - Cash inflow from operating activities totaled CNY 117,247,126.52, an increase from CNY 101,205,292.86 year-over-year[50] - Cash outflow from operating activities was CNY 165,640,837.97, compared to CNY 113,841,420.74 in the previous year, resulting in a net cash flow from operating activities of -CNY 48,393,711.45[50] Investments - The company's investment income plummeted by 88.48% to ¥699,792.26, attributed to reduced earnings from associated companies[20] - Investment income fell to CNY 699,792.26 from CNY 6,073,793.34, a decrease of approximately 88.5%[39] Shareholder Equity - The company's total owner's equity increased from ¥1,611,913,460.79 to ¥1,613,296,658.13, reflecting a growth of about 0.1%[34] - Unallocated profits increased from ¥750,669,278.57 to ¥765,087,597.92, an increase of approximately 1.7%[30] Other Financial Metrics - The weighted average return on net assets decreased by 1.52 percentage points to 0.88%[11] - The company's accounts receivable rose to ¥169,055,696.77, up from ¥146,623,662.04, indicating improved sales performance[25] - The company's other payables decreased slightly to ¥130,056,331.77 from ¥132,308,249.83, showing better cash management[28]

Financial Performance - The company's operating revenue for 2018 was CNY 608,059,265.46, representing a 14.75% increase compared to CNY 529,895,207.70 in 2017[29]. - The net profit attributable to shareholders for 2018 was CNY 135,614,826.19, an 18.77% increase from CNY 114,185,865.33 in 2017[29]. - The net profit after deducting non-recurring gains and losses was CNY 87,284,030.87, which is a 28.86% increase from CNY 67,734,905.75 in 2017[29]. - The company's total assets at the end of 2018 were CNY 1,903,079,629.30, a 5.43% increase from CNY 1,805,111,236.09 at the end of 2017[29]. - The net assets attributable to shareholders increased by 4.25% to CNY 1,635,570,001.83 at the end of 2018 from CNY 1,568,839,814.83 at the end of 2017[29]. - The basic earnings per share for 2018 was CNY 0.42, reflecting a 16.67% increase from CNY 0.36 in 2017[29]. - The company reported a net cash flow from operating activities of CNY 126,271,903.35, which is a 10.36% decrease from CNY 140,861,979.00 in 2017[29]. - The company achieved a revenue of CNY 608.06 million, representing a year-on-year growth of 14.75%[54]. - The net profit for the period was CNY 135.61 million, reflecting an increase of 18.77% compared to the previous year[54]. - The company reported a total sales revenue of ¥599,943,716.12, a 14.15% increase compared to ¥525,347,313.95 in the previous year[117]. Dividend Distribution - The company plans to distribute a cash dividend of RMB 3.00 per 10 shares, totaling an expected cash dividend payout of RMB 97.122 million[7]. - In 2018, the company distributed a cash dividend of RMB 3.00 per 10 shares, totaling RMB 97,122,000, which represents 71.62% of the net profit attributable to ordinary shareholders[156]. - The company distributed cash dividends of 0.2 yuan per share in 2018, totaling 64.748 million yuan, maintaining a stable cash dividend policy[155]. - The company has maintained a commitment to transparency regarding unallocated profits and their intended use[156]. Research and Development - The company focuses on the R&D of animal biological products and chemical drugs, including vaccines and veterinary medicines[36]. - The company adopts an "innovation-driven development" strategy, emphasizing continuous innovation in vaccine products for major animal diseases[37]. - Research and development expenses amounted to CNY 73.46 million, accounting for 12.08% of total revenue[55]. - The company has applied for 26 invention patents, with 26 patents granted, including 3 international patents[55]. - The company has developed a series of biological products focusing on new-generation genetic engineering vaccines and multi-valent vaccines for disease control in pigs and poultry[94]. - The company is focusing on research and development of new veterinary drugs, with multiple products registered in 2023, showcasing its commitment to innovation in the animal health sector[108]. Market and Sales - The company achieved a 40.37% increase in income from intellectual property transfers, contributing significantly to revenue growth[61][66]. - The revenue from distribution business reached CNY 323.75 million, a year-on-year increase of 14.80%[56]. - Direct sales revenue was CNY 229.91 million, showing a growth of 19.26% compared to the previous year[56]. - The sales model for the company includes 53.96% from distributors, 38.32% from direct sales to large farming groups, and 2.70% from government procurement[117]. - The company aims to strengthen its market presence by diversifying its product range, as evidenced by the introduction of various formulations and delivery methods for existing drugs[108]. Risk Management - The company has detailed various risks it may face in its production and operation processes in the report[9]. - The company emphasizes that forward-looking statements regarding future plans and strategies do not constitute substantive commitments to investors[8]. - The company faces risks from animal epidemics, which could significantly impact the livestock industry and the veterinary drug sector[149]. - R&D in the veterinary drug industry is characterized by high investment and long cycles, with product development taking approximately six years[150]. - The company is exposed to market competition risks due to increasing international players in the domestic market[152]. Corporate Governance - The company has received a standard unqualified audit report from Lixin Certified Public Accountants[6]. - The company has confirmed that all board members attended the board meeting for the annual report[6]. - The company has not violated decision-making procedures for external guarantees[9]. - The company has committed to ensuring the accuracy and completeness of the financial report[5]. - The company has not faced any major litigation or arbitration matters during the reporting period[187]. Investments and Acquisitions - The company became a limited partner in the CITIC Agricultural Fund with a committed investment of ¥100 million, enhancing its international acquisition capabilities[59]. - The company has made significant equity investments, including 162.75 million yuan in Zhongpu Biological, holding a 46.50% stake, and 80 million yuan in CITIC Agricultural Fund, holding a 3.72% stake[124]. - The company has ongoing non-equity investments, including 403.65 million yuan in Huizhong Biological's veterinary drug industrialization project, with a total actual investment of 156.60 million yuan[125]. Compliance and Transparency - The company guarantees that its prospectus for the initial public offering (IPO) does not contain false records or misleading statements, and it will bear legal responsibility for its authenticity and completeness[170]. - The company has committed to not distribute cash dividends or pay salaries to directors and senior management until it fulfills its public commitments if it fails to meet the commitments[170]. - The controlling shareholder has committed to repurchase shares at a price not lower than the issuance price plus interest if the IPO prospectus contains any false records or misleading statements[173].